Skip to Content

Maria Alma Rodriguez

Present Title & Affiliation

Primary Appointment

Internist and Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Vice President of Medical Affairs, Division of Ofc/EVP, Physician-in-Chief, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1485
Houston, TX 77030
Room Number: FCT18.5002

Education & Training

Degree-Granting Education

1979 University of Texas Medical School at Houston, Houston, TX, MD, AOA
1975 Our Lady of the Lake College, San Antonio, TX, BA, Chemistry and Biology, Graduate with Highest Honors

Board Certifications

4/2014 American Board of Medical Quality
1986 American Board of Medical Oncology, Certified, Meeting MOC requirements
1982 American Board of Internal Medicine, Certified, Meeting MOC requirements


Other Appointments/Responsibilities

Executive Committee, NCCN Database Disease Specific Committee, Fort Washington, PA, 1/1998-2013

Institutional Committee Activities

Member, Cancer Prevention Clinic Advisory Board, 9/2005-present
Member, President's Advisory Committee, 9/2005-2012
Member, Project Bed Task Force, 9/2005-2008
Member, Sedation and Procedures Subcommittee, 4/2005-present
Ex-officio, Clinical Effectiveness Committee, 4/2005-present
Member, Intensive Care Unit Subcommittee, 4/2005-present
Member, Council of Committee Chairs, 7/2004-present
Member, Professional Liability Committee, 7/2004-present
Ex-officio, Credential Committee of the Medical Staff, 7/2004-present
Ex-officio, Executive Committee of the Medical Staff, 7/2004-present
Member, Clinical Council, 7/2004-2012
Member, Advisory Group to the Assoc. Vice President for Clinical and Translational Research, 1/1995-present
Member, Fellowship Committee, 1/1993-1/1994
Member, Surveillance Committee (IRB), 1/1992-1/1993
Member, Perinatal Guidelines Task Force, 11/1990-12/1990
Member, Faculty Grievance Committee, 4/1990-1/1992

Honors and Awards

2013-2014 President’s Leadership Award for Advancing Women Faculty, UT MD Anderson Cancer Center
2007-present Best Doctors in America
2007 Fellow, Clinical Safety & Effectiveness (CS&E)
2001 Fellow, American College of Physicians

Professional Memberships

American Association for Cancer Research (AACR)
Member, 1994-present
American College of Medical Quality (ACMQ)
Member, 2006-present
American College of Physicians-American Society of Internal Medicine (ACP/ASIM)
Member, 1997-present
American Medical Association (AMA)
Member, 1992-present
American Society of Clinical Oncology (ASCO)
Member, 1986-present
American Society of Hematology (ASH)
Member, 1993-present
Southwest Oncology Group (SWOG)
Member, 2006-present
Texas Medical Association and Harris County Medical Society
Member, 1987-present
Texas Society of Medical Oncology (TSMO)
Member, 1989-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Dabaja B, Hess K, Shihadeh F, Podoloff D, Medeiros J, Mawlawi O, Arzu I, Oki Y, Hagemeister F, Fayad L, Reed V, Kedir A, Wogan C, Rodriguez MA. Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients with Diffuse Large B-Cell Lymphoma. Intl J of Radiat. In Press.
2. Dabaja B, Vanderplas A, Crosby-Thompson A, Abel GA, Czuczman M, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson MM, Nademanee A, Zelenetz A, LaCasce A, Rodriguez MA. Radiation for Diffuse Large B Cell Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network Lymphoma Database. Cancer. In Press.
3. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. e-Pub 7/2014. PMID: 25039868.
4. Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson MM, Nademanee AP, Niland JC, Rodig SJ, Rodriguez MA, Zelenetz AD, Lacasce AS. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer. e-Pub 4/2014. PMID: 24706502.
5. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 4/2014. e-Pub 1/2014. PMID: 24386943.
6. Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol 163(4):487-95, 11/2013. e-Pub 9/2013. PMID: 24111533.
7. Abou-Nassar KE, Vanderplas A, Friedberg JW, Abel GA, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby A, Gordon LI, Zelenetz AD, Kaminski M, Lacasce AS. Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Leuk Lymphoma 54(10):2155-62, 10/2013. e-Pub 2/25/2013. PMID: 23343180.
8. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective Phase II Study of Rituximab with Alternating Cycles of Hyper-CVAD and High-Dose Methotrexate with Cytarabine for Young Patients with High-Risk Diffuse Large B-Cell Lymphoma. Br J Haematol. e-Pub 10/2013. PMID: 24117234.
9. Evens AM, Vanderplas A, Lacasce AS, Crosby AL, Nademanee AP, Kaminski MS, Abel GA, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Zelenetz AD, Gordon LI, Friedberg JW. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: A comprehensive analysis from the NCCN lymphoma outcomes project. Cancer 119(20):3662-3671, 10/2013. e-Pub 8/2013. PMID: 23921646.
10. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical Implications of PET-Negative Residual CT Masses after Chemotherapy for Diffuse Large B-Cell Lymphoma. Leuk Lymphoma. e-Pub 5/7/2013. PMID: 23488661.
11. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk 13(1):15-8, 2/2013. e-Pub 11/6/2012. PMID: 23137719.
12. Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer 118(11):2944-51, 6/1/2012. e-Pub 10/17/2011. PMID: 22006274.
13. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A Randomized Trial of a Single-Dose Rasburicase Versus Five-Daily Doses in Patients at Risk for Tumor Lysis Syndrome. Annals of Oncology 23(6):1640-5, 6/2012. e-Pub 10/2011.
14. Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, LaCasce AS. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma 53(6):1113-6, 6/2012. e-Pub 2/3/2012. PMID: 22098406.
15. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 5/3/2012. e-Pub 2/27/2012. PMCID: PMC3359733.
16. Batty N, Hagemeister FB, Feng L, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study. Leuk Lymphoma 53(5):801-6, 5/2012. e-Pub 1/2012. PMID: 22023528.
17. Lacasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 119(9):2093-9, 3/2012. e-Pub 1/2012. PMID: 22234679.
18. Phan J, Mazloom A., Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS. Benefit of Consolidative Radiation Therapy in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Chemotherapy. Journal of Clinical Oncology. e-Pub 8/2010.
19. Rodriguez MA, Tortorella F, St John C. Improving Psychosocial Care for Improved Health Outcomes. J Healthc Qual 32(32/4):3-13, Jul-Aug, 7/2010. PMID: 20618566.
20. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez A, Samaniego F, McLaughlin PW, Hagemeister FB, Neelapu SS, Copeland AR, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II Study of Yttrium-90 (90Y)-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology 27(31):5213-8, 9/2009.
21. Rodriguez MA, Pytlik R, Kozak T, Chhanabhai M, Gascoyne R, Lu B, Deitcher SR, Winter JN. Vincristine Sulfate Liposomes Injection (Marqibo) in Heavily Pretreated Patients with Refractory Aggressive non-Hodgkin Lymphoma: Report of the Pivotal Phase 2 Study. Cancer 115(15):3475-3482, 8/2009. PMID: 19536896.
22. Rodriguez MA, Storm CD, Burris, III HA. Medical Errors: Physician and Institutional Responsibilities. Journal of Oncology Practice 5(1), 1/2009.
23. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 113(10):2734-41, 11/2008. PMID: 18973182.
24. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Combination with Rituximab in Patients with Recurrent B-cell Non-Hodgkin Lymphoma. British Journal of Haematology, 11/2008. e-Pub 9/2008.
25. Russell NC, Hoelscher DM, Janszen L, Rodriguez MA. Dietary and weight changes after treatments for lymphoma. Nutr Cancer 57(2):168-76, 2007. PMID: 17571950.
26. Liu Q, Fayad L, Cabanillas F, Hagemeister F, Ayers G, hess M, Romaguera R, Rodriguez A, Tsimberidou A, Verstovsek S, Younes A, Pro B, Lee M, Ayala A, McLaughlin P. Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 years of Treatment Experience at The University of Texas M. D. Anderson Cancer Center. J. Clin. Oncol 24, No. 10:1582-1589, 4/2006.
27. Rodriguez A. fter Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma with Rituximab plus hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine. J. Clin. Oncol. 23(28:188-193, 10/2005.
28. Rodriguez A. Reduced-intensity Allogeneic Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Disease: Low Transplant-Related Mortality and Impact of Intensity of Conditioning Regimen. Bone Marrow Transplantation 35(10):943-51, 5/2005.
29. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22:4095-102, 10/2004. PMID: 15353540.
30. Cohen L, Warneke C, Fouladi RT, Rodriguez MA. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. Cancer 100(10):2253-2260, 2004.
31. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT, Jr, Jones D, Abruzzo LV, Medeiros LJ. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98:310-4, 7/2003. PMID: 12872350.
32. Lee HK, Wilder RB, Jones D, Ha CS, Pro B, Rodriguez MA, Romaguera JE, Cabanillas F, Rodriguez J, Cox JD. Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. Leuk Lymphoma 43:1769-75, 9/2002. PMID: 12685830.
33. Wilder RB, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, Pro B, Hess MA, Cabanillas F, Cox JD. International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer 94:3083-8, 6/2002. PMID: 12115338.
34. Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F, Cox JD. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer 91(12):2440-6, 6/2001. PMID: 11413536.
35. Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemeister F, Kantarjian H, Cabanillas F. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol 11(12):1551-6, 12/2000. PMID: 11205462.
36. Rodriguez J, McLaughlin P, Hagemeister FB, Fayad L, Rodriguez MA, Santiago M, Hess M, Romaguera J, Cabanillas F. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 93(7):2202-7, 4/1999. PMID: 10090928.
37. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91(4):1178-84, 2/1998. PMID: 9454747.
38. Rodriguez MA. Factors that influence prognosis of intermediate-grade lymphomas at relapse. Cancer Treat Res 85:79-86, 1996. PMID: 9043776.
39. McLaughlin P, Hagemeister FB, Swan F, Jr, Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12:575-9, 3/1994. PMID: 8120556.
40. Woo SY, Fuller LM, Cundiff JH, Bondy ML, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Jr, Rodriguez MA, Cabanillas F, et al. Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. Int J Radiat Oncol Biol Phys 23:407-12, 1992. PMID: 1587764.


1. Palos GR, Zandstra F, Bevers T, Gilmore K, Greer M, Rodriguez MA. Improving Survivors' Quality of Care Through Use of Self-Reported Satisfaction Data. AACR Journal Cancer Research,, 1/2015. e-Pub 1/2015.
2. Nastoupil L, Neelapu S, Samaniego F, Hagemeister F, Romaguera J, Kwak L, Wang M, Fayad L, Fanale M, Oki Y, Westin J, Rodriguez MA, Cabanillas F, McLaughlin P, Fowler N. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabne, mitozantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. J Clin Oncol 32(5s):545s (#8528), 6/2014.
3. Rodriguez MA, Sanchez-Espiridion B, Gu J, Wu X, Zandstra F, Palos G. Leukocyte telomere length and risk of secondary primary tumors in long-term breast cancer suvivors. J Clin Oncol 32(5s):626s (#9599), 6/2014.
4. Rodriguez MA, DeJesus AY, Cheng L, Kroll M. Practice of venous thromboembolism (VTE) prophylaxis in hospitalized cancer patients at a comprehensive cancer center. J Clin Oncol 32(5s):440s (#6626), 6/2014.
5. Palos G, Zandstra F, Simar K, Russell L, Ozeri D, Bi W, Rodriguez MA. Tobacco use among lymphoma survivors. J Clin Oncol 32(suppl) (#e20608), 6/2014.
6. Fingeret M, Palos GR, Stepan K, Tortorella F, Rodriguez MA. Establishment and Growth of a Psychosocial Council to Address Institutional Needs Within a Comprehensive Cancer Center. Psycho-Oncology 23(Supp S1):22-23, 2/2014.
7. Zhou Z, Rademaker A, Gordon LI, LaCasce AS, Crosby-Thompson A, Vanderplas A, Rodriguez MA, Zelenetz AD, Abel A, Nademanee A, Kaminski MS, Cuzczman M, Milleson MM, Niland JC, Friedberg JW, Winter JN. Impact of Gender, Body Mass Index and Body Surface Area on Outcomes of Diffuse Large B-cell Lymphoma Patients Treated with Rituximab: Analysis of the U.S. National Comprehensive Cancer Network Database. Hematol Oncol 31(S1):166 (#208), 6/2013.
8. Dabaja B, Vanderplas A, Abel G, Czuczman MS, Friedberg J, Gordon LI, Kaminski M, LaCasce AS, Millenson M, Niland J, Nademanee AP, Zelenetz A, Crosby-Thompson AL, Rodriguez MA. Role of Radiation in Patients with Diffuse Large B-cell Lymphoma (DLBCL) in the Rituximab Era: A Comprehensive Analysis from the National Comprehensive Cancer Network (NCCN) Lymphoma Outcomes Project. Hematolo Oncol 31(S1):136 (#121), 6/2013.
9. Rodriguez MA, DeJesus YA, Cheng L, Buzdar A, Burke T. Factors Related to End-of-life Chemotherapy in Solid Tumor (ST) Patients. 2013 ASCO Annual Meeting Proceedings 31(15(Suppl)) (#9538), 5/2013.
10. Burke T, DeJesus Y, Cheng L, Buzdar A, Rodriguez MA. Pattern of Chemotherapyuse at the End-of-life in Patients with Solid Tumors (ST). 2013 ASCO Annual Meeting Proceedings 31(15 (Suppl)) (#9539), 5/2013.
11. Westin JR, Thompson MA, Cataldo VD, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy WA, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. Blood 114(22) (#3922), 11/2009.
12. Jones D, Windham J, Stewart B, Fayad L, Rodriguez A, Hagemeister FB. Differential JAK-STAT Pathway Activation in Primary Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential Cytokine Activation Patterns and Predicted Responses to Kinase Inhibitors. Blood 114(22) (#968), 11/2009.
13. Copeland AR, Cao Y, Fanale M, Fayad L, McLaughlin P, Pro B, Hagemeister F, Romaguera J, Samaniego F, Rodriguez A, Younes A. Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Results of Long Follow Up and Comparison to Institutional Historical Data. Blood 114(22) (#1680), 11/2009.
14. LaCasce A, Vandergrift JL, Rodriguez MA, Crosby AL, Lepisto EM, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Abel GA, Zelenetz AD, Friedberg JW. R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: A Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin’s Lymphoma Outcomes Database Project. Blood 114(22) (#403), 11/2009.
15. Vadhan-Raj S, Fayad L, Fanale M, Pro B, Rodriguez A, Hagemeister F, Ames K, Bueso-Ramos C, Zhou X, McLaughlin P, Fowler N, Shah J, Samaniego F, Younes A, Kwak L, Romaguera J. Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing vs. a Single Dose Followed By As Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome. Blood 114(22) (#105), 11/2009.
16. Abel GA, Vanderplas A, Friedberg JW, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby AL, Gordon LI, BlayneyDW, Zelenetz AD, LaCasce AS. Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database. Blood 114(22) (#1387), 11/2009.
17. Habra MA, Thompson MA, Rodriguez MA, Routbort MJ, Holsinger FC, Perrier ND, Waguespack SG: Primary Natural Killer/T Cell Lymphoma of the Adrenal Gland: A Unique Presentation of a Rare Disorder. Primary Natural Killer/T Cell Lymphoma of the Adrenal Gland: A Unique Presentation of a Rare Disorder. The Endocrine Society's 87th Annual Meeting 87th Annual Meeting, 2005.

Books (edited and written)

1. Rodriguez MA, Walters RS, Burke TW, Eds. 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer: New York, 2012.

Manuals, Teaching Aids, Other Teaching Publications

1. Polansky M, Rodriguez MA. Introduction to Clinical Oncology e-Course, 2/2009.

Last updated: 9/25/2015